Format

Send to

Choose Destination
Bone Marrow Transplant. 2016 Dec;51(12):1556-1560. doi: 10.1038/bmt.2016.192. Epub 2016 Jul 18.

YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome.

Author information

1
The Allogeneic Hematopoietic Cell Transplantation Laboratory, Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
2
Division of Biostatistics, Institute for Health & Society, Medical College of Wisconsin, Milwaukee, WI, USA.
3
Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
4
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
5
Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA.
6
Institute for Experimental Cellular Therapy, Universitatsklinikum Essen KMT, Essen, Germany.
7
Zentrales Knochenmarkspender-Register Deutschland, Ulm, Germany.
8
Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
9
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
10
Department of Oncology and Medicine, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
11
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
12
Laboratory of Molecular Medicine, Department of Clinical Immunology - Section 7631, Rigshospitalet, Copenhagen, Denmark.

Abstract

YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.

PMID:
27427920
PMCID:
PMC5143177
DOI:
10.1038/bmt.2016.192
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center